Search Results - "SEKI, NARIHITO"

Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score by Homma, Yukio, Yoshida, Masaki, Seki, Narihito, Yokoyama, Osamu, Kakizaki, Hidehiro, Gotoh, Momokazu, Yamanishi, Tomonori, Yamaguchi, Osamu, Takeda, Masayuki, Nishizawa, Osamu

“…Overactive bladder (OAB) is a common symptom syndrome with urgency, urinary frequency, and urgency incontinence. To collectively express OAB symptoms, we…”
Get full text

Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open‐label, controlled trial (DIrecT Study) by Yamanishi, Tomonori, Asakura, Hirotaka, Seki, Narihito, Tokunaga, Shoji

“…Objectives To evaluate the efficacy and safety of a combination therapy with dutasteride and imidafenacin in patients with benign prostatic hyperplasia and…”
Get full text

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Lower Urinary Tract Symptoms—ASSIST, Randomized Controlled Study by Yamaguchi, Osamu, Kakizaki, Hidehiro, Homma, Yukio, Takeda, Masayuki, Nishizawa, Osamu, Gotoh, Momokazu, Yokoyama, Osamu, Seki, Narihito, Yoshida, Masaki

“…Objectives To assess the efficacy and safety of solifenacin add-on therapy to tamsulosin in lower urinary tract symptoms (LUTS) men with residual overactive…”
Get full text

Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin by Shiota, Masaki, Yokomizo, Akira, Kashiwagi, Eiji, Tada, Yasuhiro, Inokuchi, Junichi, Tatsugami, Katsunori, Kuroiwa, Kentaro, Uchiumi, Takeshi, Seki, Narihito, Naito, Seiji

“…Many advanced cancers receive cisplatin‐based chemotherapy. However, cisplatin resistance is a major obstacle for cancer chemotherapy. Foxo3a is a member of…”
Get full text

Assessment of Overactive Bladder Symptoms: Comparison of 3-Day Bladder Diary and the Overactive Bladder Symptoms Score by Homma, Yukio, Kakizaki, Hidehiro, Yamaguchi, Osamu, Yamanishi, Tomonori, Nishizawa, Osamu, Yokoyama, Osamu, Takeda, Masayuki, Seki, Narihito, Yoshida, Masaki

“…Objectives To compare the Overactive Bladder Symptom Score (OABSS) and a bladder diary as a tool for assessing symptoms of overactive bladder (OAB). Methods…”
Get full text

Outline of JUA clinical guidelines for benign prostatic hyperplasia by Homma, Yukio, Gotoh, Momokazu, Yokoyama, Osamu, Masumori, Naoya, Kawauchi, Akihiro, Yamanishi, Tomonori, Ishizuka, Osamu, Seki, Narihito, Kamoto, Toshiyuki, Nagai, Atsushi, Ozono, Seiichiro

“…The Japanese Urological Association has developed Clinical Guidelines for Benign Prostatic Hyperplasia (BPH) for men with suspected BPH, which have been…”
Get full text

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study by Minato, Akinori, Furubayashi, Nobuki, Nagata, Yujiro, Tomoda, Toshihisa, Masaoka, Hiroyuki, Song, Yoohyun, Hori, Yoshifumi, Kiyoshima, Keijiro, Negishi, Takahito, Kuroiwa, Kentaro, Seki, Narihito, Tomisaki, Ikko, Harada, Kenichi, Nakamura, Motonobu, Fujimoto, Naohiro

“…Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically…”
Get full text

Effectiveness and safety of radium‐223 dichloride in patients with castration‐resistant prostate cancer and bone metastases in real‐world practice: A multi‐institutional study by Matsumoto, Takashi, Hori, Yoshifumi, Shiota, Masaki, Blas, Leandro, Nakamura, Motonobu, Seki, Narihito, Kuroiwa, Kentaro, Yokomizo, Akira, Morokuma, Futoshi, Kiyoshima, Keijiro, Eto, Masatoshi

“…Objective Radium‐223 (Ra‐223) dichloride is the bone‐targeted radioligand therapy that prolongs overall survival (OS) in patients with bone‐metastatic…”
Get full text

Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors by Negishi, Takahito, Nakagawa, Tohru, Nishiyama, Naotaka, Kitamura, Hiroshi, Okajima, Eijiro, Furubayashi, Nobuki, Hori, Yoshifumi, Kuroiwa, Kentarou, Son, Yuhyon, Seki, Narihito, Tomoda, Toshihisa, Nakamura, Motonobu

“…INTRODUCTIONMetastases from renal cell carcinoma develop in various organs. However, the breadth of discrepancy in response to immune checkpoint inhibitors…”
Get full text

P300/CBP‐associated factor regulates Y‐box binding protein‐1 expression and promotes cancer cell growth, cancer invasion and drug resistance by Shiota, Masaki, Yokomizo, Akira, Tada, Yasuhiro, Uchiumi, Takeshi, Inokuchi, Junichi, Tatsugami, Katsunori, Kuroiwa, Kentaro, Yamamoto, Ken, Seki, Narihito, Naito, Seiji

“…Twist1 has been proposed to have oncogenic properties. Although Twist1 was reported to interact with p300/CBP‐associated factor (PCAF) and to inhibit the…”
Get full text

Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study by Shiota, Masaki, Nakamura, Motonobu, Yokomizo, Akira, Tomoda, Toshihisa, Sakamoto, Naotaka, Seki, Narihito, Hasegawa, Shuji, Yunoki, Takakazu, Harano, Masahiko, Kuroiwa, Kentaro, Eto, Masatoshi

“…This multi-institutional study aimed to identify prognostic factors for cabazitaxel treatment of castration-resistant prostate cancer (CRPC). This study…”
Get full text

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study by Shiota, Masaki, Nakamura, Motonobu, Yokomizo, Akira, Tomoda, Toshihisa, Sakamoto, Naotaka, Seki, Narihito, Hasegawa, Shuji, Yunoki, Takakazu, Harano, Masahiko, Kuroiwa, Kentaro, Eto, Masatoshi

“…Objective This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC)…”
Get full text

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study) by Yamaguchi, Osamu, Kakizaki, Hidehiro, Homma, Yukio, Igawa, Yasuhiko, Takeda, Masayuki, Nishizawa, Osamu, Gotoh, Momokazu, Yoshida, Masaki, Yokoyama, Osamu, Seki, Narihito, Okitsu, Akira, Hamada, Takuya, Kobayashi, Akiko, Kuroishi, Kentaro

“…Objectives To evaluate the long‐term safety (primary objective) and efficacy (secondary objective) of antimuscarinic add‐on therapy in patients receiving…”
Get full text

Surgical procedures for benign prostatic hyperplasia: A nationwide survey in Japan by Masumori, Naoya, Kamoto, Toshiyuki, Seki, Narihito, Homma, Yukio

“…We investigated the trend in surgical procedures for benign prostatic hyperplasia (BPH) during the past 10 years in Japan. A questionnaire inquiring about the…”
Get full text

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study by Matsumoto, Takashi, Shiota, Masaki, Nakamura, Motonobu, Yokomizo, Akira, Tomoda, Toshihisa, Sakamoto, Naotaka, Seki, Narihito, Hasegawa, Shuji, Yunoki, Takakazu, Harano, Masahiko, Kuroiwa, Kentaro, Eto, Masatoshi

“…There is little data on the outcome of cabazitaxel (CBZ) treatment of elderly patients with castration-resistant prostate cancer (CRPC). This study assessed…”
Get full text

Holmium laser enucleation for prostatic adenoma: analysis of learning curve over the course of 70 consecutive cases by Seki, Narihito, Mochida, Osamu, Kinukawa, Naoko, Sagiyama, Kazuyuki, Naito, Seiji

“…We elucidate the learning curve, efficacy and safety of holmium laser enucleation of prostatic adenomas. We retrospectively reviewed data on 70 patients who…”
Get more information

Site-specific Response to Nivolumab in Renal Cell Carcinoma by NEGISHI, TAKAHITO, FURUBAYASHI, NOBUKI, NAKAGAWA, TOHRU, NISHIYAMA, NAOTAKA, KITAMURA, HIROSHI, HORI, YOSHIFUMI, KUROIWA, KENTAROU, SON, YUHYON, SEKI, NARIHITO, TOMODA, TOSHIHISA, OKAJIMA, EIJIRO, NAKAMURA, MOTONOBU

Get full text

Perioperative management of transurethral surgery for benign prostatic hyperplasia: A nationwide survey in Japan by Okamura, Kikuo, Nojiri, Yoshikatsu, Seki, Narihito, Arai, Yoichi, Matsuda, Tadashi, Hattori, Ryohei, Hasegawa, Tomonori, Naito, Seiji

“…Objectives:  Various types of minimally invasive surgical treatments, including transurethral resection of prostate (TURP), are being carried out in Japan for…”
Get full text

Comparison of photoselective vaporization and standard transurethral resection of the prostate on urodynamics in patients with benign prostatic hyperplasia by Nomura, Hiroyuki, Seki, Narihito, Yamaguchi, Akito, Naito, Seiji

“…Objectives:  To compare photoselective vaporization of the prostate (PVP) and transurethral resection of the prostate (TURP) in patients with benign prostatic…”
Get full text

Holmium laser enucleation of the prostate: comparison of outcomes according to prostate size in 97 Japanese patients by Seki, Narihito, Tatsugami, Katsunori, Naito, Seiji

“…To review the outcomes associated with holmium laser enucleation of the prostate (HoLEP) to identify the efficacy and safety in relation to the prostate size…”
Get more information